BIOLINERX LTD/S (NASDAQ:BLRX) Stock Price Down 26.1%

BIOLINERX LTD/S (NASDAQ:BLRX) shares fell 26.1% during trading on Thursday . The company traded as low as $1.55 and last traded at $2.04, 1,131,490 shares changed hands during trading. An increase of 1,337% from the average session volume of 78,758 shares. The stock had previously closed at $2.76.

BLRX has been the topic of a number of recent analyst reports. HC Wainwright restated a “neutral” rating on shares of BIOLINERX LTD/S in a research note on Wednesday, August 7th. Zacks Investment Research downgraded shares of BIOLINERX LTD/S from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $4.75.

The company has a debt-to-equity ratio of 0.18, a current ratio of 3.14 and a quick ratio of 3.14. The firm has a market capitalization of $20.64 million, a P/E ratio of -0.65 and a beta of 1.62. The firm’s fifty day moving average price is $2.66 and its 200-day moving average price is $2.20.

Large investors have recently made changes to their positions in the stock. Phoenix Holdings Ltd. bought a new stake in BIOLINERX LTD/S during the third quarter worth approximately $65,000. NEXT Financial Group Inc boosted its stake in BIOLINERX LTD/S by 82.5% during the 2nd quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 33,000 shares in the last quarter. Delek Group Ltd. boosted its stake in BIOLINERX LTD/S by 74.0% during the 2nd quarter. Delek Group Ltd. now owns 375,047 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 159,469 shares in the last quarter. Finally, Morgan Stanley boosted its stake in BIOLINERX LTD/S by 50.6% during the 2nd quarter. Morgan Stanley now owns 1,421,862 shares of the biotechnology company’s stock valued at $519,000 after purchasing an additional 477,798 shares in the last quarter. 39.24% of the stock is currently owned by hedge funds and other institutional investors.

About BIOLINERX LTD/S (NASDAQ:BLRX)

BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Further Reading: Margin

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.